Literature DB >> 3524443

Evaluation of laboratory diagnosis of toxoplasmosis by means of an ELISA-triple test. Detection of class specific IgG, IgM and circulating antigen.

F van Knapen, S O Panggabean, J van Leusden.   

Abstract

The combination of three parameters (IgG, IgM and circulating antigen) in a so-called 'ELISA triple test' was suggested for advantageous diagnosing of human toxoplasmosis. A qualitative assay was used with the following arbitrary assumptions: IgG antibodies reflect an infection, IgM antibodies reflect a recent (primary) infection and circulating antigens reflect an active infection. The three assays were performed simultaneously in one microtiter plate. This approach was tested with 1091 patient sera submitted for routine diagnosis. In comparison with conventional indirect immunofluorescence and complement fixation test it was observed that combinations indicating a recently acquired infection (combinations with IgM and/or circulating antigen) mainly paralleled low or negligible conventional antibody titers. No strict association was seen between particular combinations and certain clinical symptoms suggestive for toxoplasmosis. In conclusion it was stated that the triple test for support of clinical diagnosis has some advantages but that a strong need exists to be able to demonstrate exacerbation or reinfections which are generally not characterised by IgM antibody formation of free circulating antigens but may be the reason for elevated conventional antibody titers.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524443     DOI: 10.1007/bf00402682

Source DB:  PubMed          Journal:  Antonie Van Leeuwenhoek        ISSN: 0003-6072            Impact factor:   2.271


  10 in total

1.  Value of lymph-node biopsy in the diagnosis of acute acquired toxoplasmosis.

Authors:  R F Dorfman; J S Remington
Journal:  N Engl J Med       Date:  1973-10-25       Impact factor: 91.245

2.  IgM antibodies in acute toxoplasmosis. I. Diagnostic significance in congenital cases and a method for their rapid demonstration.

Authors:  J S Remington; M J Miller; I Brownlee
Journal:  Pediatrics       Date:  1968-06       Impact factor: 7.124

3.  IgM antibodies in acute toxoplasmosis. II. Prevalence and significance in acquired cases.

Authors:  J S Remington; M J Miller; I Brownlee
Journal:  J Lab Clin Med       Date:  1968-05

4.  A new soluble antigen preparation of Toxoplasma gondii and its use in serological diagnosis.

Authors:  H P Hughes; F Van Knapen; H J Atkinson; A H Balfour; D L Lee
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

5.  The enzyme-linked immunosorbent assay and its application to parasitic infections.

Authors:  E J Ruitenberg; F van Knapen
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

6.  Detection of toxoplasma antigen in tissues by means of enzyme-linked immunosorbent assay (ELISA).

Authors:  F van Knapen; S O Panggabean
Journal:  Am J Clin Pathol       Date:  1982-06       Impact factor: 2.493

7.  Laboratory diagnosis of toxoplasmosis by means of an ELISA triple test (detection of class-specific IgG, IgM and circulating antigens).

Authors:  F van Knapen; S O Panggabean
Journal:  Antonie Van Leeuwenhoek       Date:  1980       Impact factor: 2.271

8.  Detection of circulating antigen during acute infections with Toxoplasma gondii by enzyme-linked immunosorbent assay.

Authors:  F van Knapen; S O Panggabean
Journal:  J Clin Microbiol       Date:  1977-12       Impact factor: 5.948

9.  Detection of circulating antigen in acute experimental infections with Toxoplasma gondii.

Authors:  R E Raizman; F A Neva
Journal:  J Infect Dis       Date:  1975-07       Impact factor: 5.226

10.  Antigenemia in recently acquired acute toxoplasmosis.

Authors:  F G Araujo; J S Remington
Journal:  J Infect Dis       Date:  1980-02       Impact factor: 5.226

  10 in total
  1 in total

Review 1.  Serodiagnosis of parasitic diseases.

Authors:  S E Maddison
Journal:  Clin Microbiol Rev       Date:  1991-10       Impact factor: 26.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.